Siga Technologie Stock Price, News & Analysis

SIGA (Nasdaq: SIGA) will host a business update webcast and conference call on Thursday, November 6, 2025 at 4:30 P.M. ET following release of third-quarter 2025 results.

Management participants include Diem Nguyen, CEO, and Daniel Luckshire, CFO. The live webcast will be available in the Investor Relations section of the company website and by dialing the domestic or international conference numbers. A replay will be available for two weeks with Conference ID 1141989. Attendees are asked to log in 5–10 minutes before the start time.

SIGA Technologies (NASDAQ: SIGA) reported strong financial results for Q2 2025, with significant product revenue growth. The company generated $79.1 million in product sales, primarily from delivering oral TPOXX ($53 million) and IV TPOXX ($26 million) to the Strategic National Stockpile.

The company secured additional development funding of $27 million under the BARDA 19C contract, including $13 million for the TPOXX pediatric program and $14 million for manufacturing support activities. Net income reached $35.5 million ($0.49 per diluted share), compared to $1.8 million ($0.03 per share) in Q2 2024.

SIGA also declared and paid a special cash dividend of $0.60 per share to shareholders of record as of April 29, 2025.

SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for August 5, 2025, at 4:30 PM ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's second-quarter 2025 results.

Investors can access the call through a domestic dial-in (1-800-717-1738) or international dial-in (1-646-307-1865). A replay will be available for two weeks, and the webcast will be accessible through SIGA's investor relations website.

SIGA Technologies (NASDAQ: SIGA) reported Q1 2025 financial results with total revenues of $7.0 million, down from $25.4 million in Q1 2024. The company posted a net loss of $0.4 million or $(0.01) per share. Key highlights include: a $26 million IV TPOXX procurement order from the U.S. Government, $94 million in outstanding orders for the Strategic National Stockpile, and regulatory approval in Japan for TPOXX (TEPOXX) treatment of smallpox, mpox, cowpox, and vaccination complications. In April 2025, SIGA delivered approximately $62 million worth of TPOXX to the SNS and declared a special cash dividend of $0.60 per share. The company also secured a $14 million contract modification for manufacturing support and completed a $6 million international sale.

SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for May 8, 2025, at 4:30 P.M. ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's first-quarter 2025 results.

Investors can access the call through the company's website at www.siga.com or by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A two-week replay will be available via phone using Conference ID: 1160299.

SIGA Technologies (NASDAQ: SIGA) has declared a special cash dividend of $0.60 per share on its common stock, marking the fourth consecutive year of special dividend payments. The dividend matches the level declared in March 2024 and will be payable on May 15, 2025, to shareholders of record as of April 29, 2025.

CEO Diem Nguyen highlighted that this dividend declaration reflects the company's strong balance sheet and continued confidence in its business future, emphasizing their commitment to disciplined financial management and strategic execution for long-term shareholder value.

SIGA Technologies (Nasdaq: SIGA) has appointed Retired U.S. Army General John 'Jack' Keane to its Board of Directors, effective immediately. General Keane, a four-star general who served as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003, brings 37 years of public service experience.

As a foreign policy and national security expert, General Keane currently serves as Chairman of the Institute for the Study of War since 2007 and President of GSI, since 2004. He is a recipient of the Presidential Medal of Freedom and the first military leader honored with the Ronald Reagan Peace Through Strength Award.

The appointment aims to leverage General Keane's expertise in national security and biodefense preparedness to support SIGA's mission of expanding its FDA-approved antiviral TPOXX distribution to the U.S. strategic national stockpile and international governments.

SIGA Technologies (NASDAQ: SIGA) reported strong financial results for 2024, achieving $133 million in product sales and $70 million in pre-tax operating income, resulting in $59 million in net income. The company marked its second consecutive year of product revenue growth.

The sales breakdown includes:

• $100 million in oral and IV TPOXX sales to U.S. Strategic National Stockpile
• $10 million to U.S. Department of Defense
• $23 million in international sales

SIGA has received TPOXX procurement orders from 30 countries over the past three years, with sales to 13 countries in 2024, including its first sale in Africa to Morocco. In January 2025, TPOXX (TEPOXX) received regulatory approval in Japan for treating smallpox, mpox, cowpox, and vaccination complications in adults and pediatric patients weighing at least 13 kg.

SIGA Technologies (Nasdaq: SIGA) has scheduled a business update conference call and webcast for March 11, 2025, at 4:30 P.M. ET, following the release of its fourth-quarter and full year 2024 financial results.

The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Investors can access the call through:

• Domestic dial-in: 1-800-717-1738
• International dial-in: 1-646-307-1865
• Company website: www.siga.com (Investor Relations section)

A two-week replay will be available via domestic (1-844-512-2921) and international (1-412-317-6671) numbers using Conference ID: 1152574. The webcast will be archived in the Investor Relations section.